Jazz Pharmaceuticals
Clinical trials sponsored by Jazz Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on neuroscience and oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors Results expected Sep 2026 (estimated)
- New antibody drug targets HER2 cancers in broad trial Results expected Dec 2026 (estimated)
- CBD epilepsy drug under Real-World watch for rare seizure disorders Results expected Feb 2027 (estimated)
- First human test of JZP269: can this experimental drug pass the safety check? Results expected Feb 2027 (estimated)
- Epidiolex liver check: is Long-Term use safe? Results expected Aug 2027 (estimated)
-
Can a new drug cut seizure days in juvenile myoclonic epilepsy?
Disease control Not yet recruitingThis trial tests whether an experimental drug called JZP926 can safely reduce the number of days people aged 10 and older experience myoclonic seizures—brief, shock-like jerks—due to juvenile myoclonic epilepsy. Participants are randomly assigned to receive either JZP926 or a pla…
Phase 2/3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a slow start with CBD oil tame Hard-to-Control seizures?
Disease control Not yet recruitingThis trial tests whether a gradual dosing schedule of cannabidiol oral solution (CBD-OS) can help reduce seizures in adults with Lennox-Gastaut syndrome, a severe form of epilepsy. Participants will take CBD oil alongside their usual seizure medications. The study measures how ma…
Phase 4 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
Disease control Not yet recruitingThis study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can CBD tame seizures in severe childhood epilepsy? a major trial aims to find out
Disease control Not yet recruitingThis phase 3 trial is testing whether a cannabidiol oral solution (CBD-OS) can safely reduce seizures in people aged 1 year and older with developmental and epileptic encephalopathy (DEE), a group of severe epilepsy syndromes. Participants receive either CBD or a placebo twice da…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
First human test of JZP269: can this experimental drug pass the safety check?
Knowledge-focused Not yet recruitingResearchers are running a Phase 1 trial of JZP269, an experimental drug, in healthy adults aged 18 to 55. The study gives single doses that increase step by step, with some participants receiving placebo, to check safety and tolerability. Blood tests will measure how the body abs…
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC